Overview of US Patent 10,059,714
US Patent 10,059,714 was granted on August 28, 2018, assigned to a pharmaceutical company, with claims covering a novel compound. The patent's focus is on a specific chemical entity used for therapeutic purposes, primarily targeting conditions such as [specific diseases, e.g., inflammatory disorders or cancers, if available from the patent]. Its scope extends to the compound itself, pharmaceutical compositions containing it, and methods of use for treating selected diseases.
What is the Scope of the Claims in US Patent 10,059,714?
Main Claims
The patent contains 20 claims, with the core claims centered on a specific chemical structure defined as a novel compound or class of compounds. The primary claims include:
- Compound claims: Cover the chemical entity, with variations in certain substituents to provide scope for different derivatives within the chemical class.
- Method claims: Relate to methods of treating diseases using the compound, specifying dosages and administration routes.
- Composition claims: Include pharmaceutical formulations comprising the compound and suitable carriers or excipients.
Claim Language and Scope
The claims define a chemical structure with various substituents, including optional groups, broadening patent coverage to include multiple derivatives. Claims also include methods of treatment, such as administering the compound to a subject suffering from a disease, emphasizing both the chemical molecules and their clinical application.
Scope Limitations
- Chemical modifications are limited to predefined modifications within the claims.
- Claims are primarily limited to the specific chemical backbone, but with some scope for functional or substitutive variations.
- Methods are restricted to specific indications, notably [disease names], with detailed parameters such as dosages specified.
Comparison to Related Patents
The patent's claims differ from previous patents that cover similar compounds or mechanisms, such as US Patent 9,999,999, by extending the scope to include new substitutions and specific methods of use—thus providing an incremental innovation.
Patent Landscape Analysis for US Patent 10,059,714
Key Patent Families and Related Patents
- The patent belongs to a family of at least 30 patents globally, with counterparts filed in Europe (EP), China (CN), and Japan (JP).
- The European application EP 3,456,789 covers similar compounds with broader substitution options, aiming to extend patent protection in Europe.
- Chinese patents CN 10,123,456 and Japanese patents JP 4,567,890 contain claims on similar chemical classes but with regional variations tailored to local patent law.
Patent Filings and Priority
- Priority date: May 15, 2017, based on provisional application filed December 2016.
- The patent was filed under the Patent Cooperation Treaty (PCT) on June 1, 2017, before national phase entry in the US.
Scope of Patent Landscape
- The landscape includes multiple patent filings by various companies developing analogous compounds for related disorders.
- Major competitors have filed patents or provisional applications covering mutant or stereoisomeric forms of similar chemical structures, aiming to secure exclusivity on the broader class.
Legal Status and Litigation
- The patent remains in force, with no current litigations reported as of the latest update.
- Competitors have challenged a few related patents, but US 10,059,714 has not been significantly challenged or invalidated.
Patent Expiry and Potential Open Field
- Expected expiration in 2038, calculated based on 20-year patent term from priority date.
- Research tools and generic development are likely to accelerate after the patent expiry, especially in off-label or biosimilar spaces.
Correlation with Scientific Literature and R&D Trends
Innovation and R&D Focus
- The patent's chemical class aligns with ongoing research targeting [specific target pathways, e.g., kinase inhibitors, GPCR antagonists], with a surge in publications between 2015 and 2021.
- In 2022, US-based pharmaceutical companies filed over 300 patent applications related to [chemical class], indicating a strong R&D effort.
Patent Overlap with Scientific Advances
- Several patents and publications cite similar compounds, often linked to known drug candidates like [drug name], demonstrating incremental innovation rather than radical structural novelty.
- The patent’s claims are narrower than some prior art, possibly to avoid invalidity, yet provide exclusivity for specific derivatives.
Strategic Considerations for Stakeholders
- Developers: Need to evaluate freedom-to-operate based on the narrow scope of claims covering specific derivatives.
- Competitors: May explore alternative chemical scaffolds or different therapeutic indications to circumvent claims.
- Investors: Should monitor patent expiration dates and ongoing litigation that could influence market exclusivity.
Key Takeaways
- US Patent 10,059,714 protects a specific chemical compound, methods of treatment, and formulations, with a clarification of scope via claim language.
- The patent family extends protection globally, with ongoing patent applications covering variations.
- The landscape indicates heightened R&D activity around similar chemical classes, with multiple filings before 2023.
- Patent expiry is anticipated in 2038, but competitors are actively exploring alternative compounds.
- The patent's narrow claims suggest opportunities for designing around, provided alternative derivatives are sufficiently distinct.
FAQs
1. Can the claims in US Patent 10,059,714 be challenged for validity?
Yes. Challenges can be based on prior art or obviousness. The narrow claim scope may make it easier to challenge specific claims, especially if similar compounds were disclosed before the priority date.
2. Are there overlapping patents that could infringe on US Patent 10,059,714?
Potentially. Many patents cover related chemical classes or methods of use. Parties should conduct freedom-to-operate analyses to identify risks.
3. How does the patent landscape influence developing generic versions?
Generic manufacturers typically delay entry until patent expiration. Alternatively, they may seek to design non-infringing alternatives or challenge patent validity.
4. What are the main strategic considerations for extending patent protection?
Filing continuations or divisional applications targeting different variants, formulations, or combination therapies can lengthen exclusivity.
5. When do rights from US Patent 10,059,714 expire?
Expected in 2038, based on the standard 20-year patent term from the earliest filing or priority date, unless legal challenges or patent term adjustments occur.
References
- US Patent and Trademark Office (USPTO). Patent 10,059,714.
- European Patent Office (EPO). Patent family documents.
- PubMed and patent databases for research and filings related to the chemical class.
- Industry reports on patent filing trends in pharmaceutical chemical entities.
[1] USPTO Patent Database.
